Features of diagnostics and treatment of the patient with slowly evolving immune-mediated diabetes and multiple complications
https://doi.org/10.14341/DM13383
Abstract
Slowly developing immune-mediated diabetes mellitus in adults combines the phenotypic and immunological characteristics of type 1 and type 2 diabetes mellitus, which often complicates the correct diagnosis and timely initiation of appropriate glucose-lowering therapy. The article presents a clinical case of a 46-year-old patient with slowly evolving immune-mediated diabetes with multiple complications, initially diagnosed as type 2 diabetes mellitus, upon hospitalization in a surgical hospital for phlegmon of the right foot. A feature of the clinical case is the complications, the severity of which did not correspond to the known duration of the disease and was due to a "hidden", long-term course. The correct diagnosis established during the diagnostic search will avoid attempts to prescribe incorrect therapy to the patient in the future, which can lead to decompensation of carbohydrate metabolism and progression of late complications. With this article, we want to draw the attention of endocrinologists and doctors of other specialties to the complexity, diversity of the clinical course of LADA diabetes and the need for differential diagnosis, a detailed collection of the disease history, as well as the importance of determining autoantibodies in the atypical course of type 2 diabetes mellitus.
About the Authors
M. V. Yaroslavceva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Marianna V. Yaroslavceva, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
D. A. Kataeva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Daria A. Kataeva, MD, clinical resident
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
G. R. Galstyan
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Gagik R. Galstyan, MD, PhD, Professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
O. N. Bondarenko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Olga N. Bondarenko, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
References
1. Kononenko IV, Smirnova OM, Mayorov AY, Shestakova MV. Classification of diabetes. World Health Organization 2019. What’s new? Diabetes mellitus. 2020;23(4):329-339. (In Russ.) doi: https://doi.org/10.14341/DM12405
2. Liu B, Xiang Y, Liu Z, Zhou Z. Past, present and future of latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2020;36(1):e3205. doi: https://doi.org/10.1002/dmrr.3205
3. Ramu D, Ramaswamy S, Rao S, Paul SFD. The worldwide prevalence of latent autoimmune diabetes of adults among adult-onset diabetic individuals: a systematic review and meta-analysis. Endocrine. 2023;82(1):28-41. doi: https://doi.org/10.1007/s12020-023-03424-5
4. Tang X, Yan X, Zhou H, et al. Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes. Diabetes Metab Syndr Obes. 2019;12:1527-1541. doi: https://doi.org/10.2147/DMSO.S202193
5. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulindependent onset of disease. Diabetes. 1993;42(2):359-362. doi: https://doi.org/10.2337/diab.42.2.359
6. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206-2212. doi: https://doi.org/10.1007/s00125-005-1960-7
7. Bondarenko ON, Yaroslavceva MV, Galstyan GR, Mokrysheva NG. Arterial mediacalcinosis in patients with diabetes mellitus: etiopathogenetic and histopathological aspects. Problems of endocrinology. 2025;71(1):50-59. (In Russ.) doi: https://doi.org/10.14341/probl13360
8. Maddaloni E, Coleman RL, Agbaje O, et al. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the uk prospective diabetes study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 2020;8(3):206–215. doi: https://doi.org/10.1016/S2213-8587(20)30003-6
9. Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013;36(4):908-913. doi: https://doi.org/10.2337/dc12-0931
10. Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003;26(2):452-457. doi: https://doi.org/10.2337/diacare.26.2.452
11. Buzzetti R, Tuomi T, Mauricio D, et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes. 2020;69(10):2037-2047. doi: https://doi.org/10.2337/dbi20-0017
12. Lin T, Cai Y, Tang L, Lian Y, Liu M, Liu C. Efficacy and safety of sitagliptin and insulin for latent autoimmune diabetes in adults: A systematic review and meta-analysis. J Diabetes Investig. 2022;13(9):1506-1519. doi: https://doi.org/10.1111/jdi.13814
13. Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37(1):e11-e12. doi: https://doi.org/10.2337/dc13-1523
14. Maddaloni E, Naciu AM, Mignogna C, et al. Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study. Diabetes Obes Metab. 2024;26(5):1670-1677. doi: https://doi.org/10.1111/dom.15469
Supplementary files
|
|
1. Figure 1. Lower extremities of patient M. (A — wound of the left heel at admission to the Diabetic Foot Department of the Institute of Diabetes, Endocrinology Research Centre; B — appearance of the lower extremities). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(944KB)
|
Indexing metadata ▾ | |
|
|
2. Figure 2. Phlegmon of the right foot in patient M. (before amputation, June 2024). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(443KB)
|
Indexing metadata ▾ | |
|
|
3. Figure 3. Fundus appearance in patient M. Optic disc: multiple retinal hemorrhages (indicated by black arrowheads) along the vessels, soft exudates (indicated by white arrows). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(475KB)
|
Indexing metadata ▾ | |
|
|
4. Figure 4. Posterior tibial artery of the left lower leg. B-mode ultrasound. Relatively uniform increase in vascular wall echogenicity combined with loss of layer differentiation and multiple calcifications (arrow). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(502KB)
|
Indexing metadata ▾ | |
|
|
5. Figure 5. X-ray of the left foot, lateral view. The arrow indicates a forming focus of osteonecrosis and wound-related soft tissue rarefaction. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(304KB)
|
Indexing metadata ▾ | |
|
|
6. Figure 6. Left heel region of patient M. two weeks after discharge. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(498KB)
|
Indexing metadata ▾ | |
Review
For citations:
Yaroslavceva M.V., Kataeva D.A., Galstyan G.R., Bondarenko O.N. Features of diagnostics and treatment of the patient with slowly evolving immune-mediated diabetes and multiple complications. Diabetes mellitus. 2026;29(1):50-56. (In Russ.) https://doi.org/10.14341/DM13383
Views:
1172
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
